123 related articles for article (PubMed ID: 10425097)
1. Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.
Bergeron RJ; McManis JS; Bussenius J; Brittenham GM; Wiegand J
J Med Chem; 1999 Jul; 42(15):2881-6. PubMed ID: 10425097
[TBL] [Abstract][Full Text] [Related]
2. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Weimar WR; Vinson JR; Bussenius J; Yao GW; McManis JS
J Med Chem; 1999 Jan; 42(1):95-108. PubMed ID: 9888836
[TBL] [Abstract][Full Text] [Related]
3. The desferrithiocin pharmacophore.
Bergeron RJ; Liu CZ; McManis JS; Xia MX; Algee SE; Wiegand J
J Med Chem; 1994 May; 37(10):1411-7. PubMed ID: 8182699
[TBL] [Abstract][Full Text] [Related]
4. Desferrithiocin analogue based hexacoordinate iron(III) chelators.
Bergeron RJ; Huang G; Weimar WR; Smith RE; Wiegand J; McManis JS
J Med Chem; 2003 Jan; 46(1):16-24. PubMed ID: 12502356
[TBL] [Abstract][Full Text] [Related]
5. Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.
Bergeron RJ; Wiegand J; McManis JS; McCosar BH; Weimar WR; Brittenham GM; Smith RE
J Med Chem; 1999 Jul; 42(13):2432-40. PubMed ID: 10395484
[TBL] [Abstract][Full Text] [Related]
6. Desferrithiocin analogues and nephrotoxicity.
Bergeron RJ; Wiegand J; McManis JS; Bharti N; Singh S
J Med Chem; 2008 Oct; 51(19):5993-6004. PubMed ID: 18788724
[TBL] [Abstract][Full Text] [Related]
7. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Bergeron RJ; Wiegand J; Bharti N; McManis JS
J Med Chem; 2012 Aug; 55(16):7090-103. PubMed ID: 22889170
[TBL] [Abstract][Full Text] [Related]
8. The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.
Bergeron RJ; Bharti N; Wiegand J; McManis JS; Singh S; Abboud KA
J Med Chem; 2010 Apr; 53(7):2843-53. PubMed ID: 20232803
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of orally administered desferrithiocin analogs in cebus apella primates.
Bergeron RJ; Weimar WR; Wiegand J
Drug Metab Dispos; 1999 Dec; 27(12):1496-8. PubMed ID: 10570032
[TBL] [Abstract][Full Text] [Related]
10. The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
Bergeron RJ; Wiegand J; Ratliff-Thompson K; Weimar WR
Ann N Y Acad Sci; 1998 Jun; 850():202-16. PubMed ID: 9668541
[TBL] [Abstract][Full Text] [Related]
11. Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.
Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Park JH; Eiler-McManis E; Bergeron J; Brittenham GM
J Med Chem; 2005 Feb; 48(3):821-31. PubMed ID: 15689166
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
Bergeron RJ; Wiegand J; McManis JS; Bharti N; Singh S
J Med Chem; 2008 Jul; 51(13):3913-23. PubMed ID: 18533709
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators.
Bergeron RJ; Wiegand J; Wollenweber M; McManis JS; Algee SE; Ratliff-Thompson K
J Med Chem; 1996 Apr; 39(8):1575-81. PubMed ID: 8648596
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships among desazadesferrithiocin analogues.
Bergeron RJ; Wiegand J; McManis JS; Weimar WR; Huang G
Adv Exp Med Biol; 2002; 509():167-84. PubMed ID: 12572994
[TBL] [Abstract][Full Text] [Related]
15. The design, synthesis, and evaluation of organ-specific iron chelators.
Bergeron RJ; Wiegand J; McManis JS; Bharti N
J Med Chem; 2006 Nov; 49(24):7032-43. PubMed ID: 17125256
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
[TBL] [Abstract][Full Text] [Related]
17. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
[TBL] [Abstract][Full Text] [Related]
18. Desferrithiocin: a search for clinically effective iron chelators.
Bergeron RJ; Wiegand J; McManis JS; Bharti N
J Med Chem; 2014 Nov; 57(22):9259-91. PubMed ID: 25207964
[TBL] [Abstract][Full Text] [Related]
19. Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
Bergeron RJ; Wiegand J; Weimar WR; Lindstrom TC; Fannin TL; Ratliff-Thompson K
Comp Med; 2004 Dec; 54(6):664-72. PubMed ID: 15679265
[TBL] [Abstract][Full Text] [Related]
20. Development of tridentate iron chelators: from desferrithiocin to ICL670.
Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
